LYR-210
Chronic Rhinosinusitis (CRS)
Phase 3Active; Clinical plan announced Oct 2025
Key Facts
Indication
Chronic Rhinosinusitis (CRS)
Phase
Phase 3
Status
Active; Clinical plan announced Oct 2025
Company
About Lyra Therapeutics
Lyra Therapeutics is focused on transforming the treatment paradigm for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million people in the United States. The company leverages its proprietary drug-eluting nasal mesh technology to deliver sustained, localized therapy directly to the disease site, aiming to break the cycle of ineffective medical management. With its lead candidate, LYR-210, in Phase 3 development and a second candidate, LYR-220, in its pipeline, Lyra is positioned to address a large, underserved market. The company is publicly traded and led by an experienced team of drug developers.
View full company profileTherapeutic Areas
Other Chronic Rhinosinusitis (CRS) Drugs
| Drug | Company | Phase |
|---|---|---|
| LYR-220 | Lyra Therapeutics | Not Specified (Pipeline) |